Strobeck Matthew

Average Profitability
6.55%
Insider Buys Quantity
15
Insider Buys Sum
$22.06M
Insider Sells Quantity
0
Insider Sells Sum
$0

Insider Activity of Strobeck Matthew

According to the SEC Form 4 filings, Strobeck Matthew, being in a position of

  1. director at Accelerate Diagnostics, Inc.,
    оver the last 12 months, has bought 100000 shares for $150,000, and sold 0 shares,
    over all time since 2014-08-04, has bought 426470 shares for $5.41M, and sold 0 shares.

The largest purchase of all time was on 2015-12-15 and amounted to 176470 shares of Accelerate Diagnostics, Inc. for $3M.

Biography of Strobeck Matthew

No biography is available at this moment.

2024-01-23PurchaseAccelerate Diagnostics, Inc.
AXDX
director
100,000
0.7643%
$1.50$150,000-11.36%
2022-11-21PurchaseBiodesix, Inc.
BDSX
director
2.34M
3.5863%
$1.15$2.69M+22.69%
2022-11-21PurchaseBiodesix, Inc.
BDSX
director
4.69M
7.1727%
$1.15$5.39M+22.69%
2022-04-07PurchaseBiodesix, Inc.
BDSX
1.68M
4.2712%
$1.79$3M-3.91%
2021-12-30PurchaseBiodesix, Inc.
BDSX
director
295,600
1.0655%
$4.35$1.29M-60.43%
2020-10-30PurchaseBiodesix, Inc.
BDSX
director
166,666
4.9886%
$18.00$3M+19.87%
2020-09-03PurchaseQuidelOrtho Corporation
QDEL
director
400
0.0009%
$155.63$62,254-4.68%
2020-09-02PurchaseQuidelOrtho Corporation
QDEL
director
7,300
0.0172%
$166.65$1.22M-9.74%
2020-03-18PurchaseAccelerate Diagnostics, Inc.
AXDX
director
10,000
0.0183%
$7.11$71,100+41.58%
2017-01-09PurchaseAccelerate Diagnostics, Inc.
AXDX
director
16,000
0.0288%
$19.00$304,000+20.27%
2016-02-09PurchaseAccelerate Diagnostics, Inc.
AXDX
director
40,000
0.0794%
$11.52$460,800+79.17%
2015-12-15PurchaseAccelerate Diagnostics, Inc.
AXDX
director
176,470
0.3064%
$17.00$3M-13.43%
2015-03-19PurchaseAccelerate Diagnostics, Inc.
AXDX
director
4,000
0.009%
$22.04$88,160-12.12%
2014-08-05PurchaseAccelerate Diagnostics, Inc.
AXDX
director
40,000
0.094%
$16.70$668,000+37.01%
2014-08-04PurchaseAccelerate Diagnostics, Inc.
AXDX
director
40,000
0.0923%
$16.70$668,000+34.17%
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.